Pilot Study: Paclitaxel plus Bevacizumab followed by FEC100 in HER2-negative locally (stage IIIB/IIIC) advanced breast cancer.

Pilot Study: Paclitaxel plus Bevacizumab followed by FEC100 in HER2-negative locally (stage IIIB/IIIC) advanced breast cancer. - Paclitaxel plus Bevacizumab followed by FEC100 in HER2-negative locally advanced breast cancer. (KBOG-1201)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009978

Enrollment

Registered

2013-02-06

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Administrate 4 cycles of combination with Paclitaxe and Bevacizumab follwed by 4 cycles of FEC100. Operation is performed after chemotherapy.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Unresectable locally advanced(stage IIIB/IIIC) breast cancer 2.HER2 negative confirmed by IHC or FISH 3.Previously untreated with chemotherapy, radiationtherapy, endocrinetherapy and immunotherapy for locally advanced breast cancer 4.N3 confirmed by histological diagnosis or cytodiagnosis 5.ECOG performance status 0-1 6.Having at least one measureable lesion

Exclusion criteria

Exclusion criteria: 1) Patient with a history of the past of the breast cancer 2) Ineligible based on decision of an investigator

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
non residual tumor classification rate pathological complete response rate safety progression-free survival 3years survival rate	—

Countries

Japan

Contacts

Public ContactNaoki Niikura

Tokai University School of Medicine Department of Breast and Endocrine Surgery

niikura@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026